还剩1页未读,继续阅读
文本内容:
原文三阴性乳腺癌是雌激素受体、孕酮受体和HER2检测皆为阴性的乳腺癌由于这种生物学特征,这些癌症不会对内分泌疗法或曲妥珠单抗做出反应“在其他乳腺癌亚型中,你可以使用这些药物取得一些胜利但是目前三阴性乳腺癌目前缺乏治疗靶标,而且是用传统的化学疗法治疗的,”医学博士、美国费城的托马斯•杰弗逊高校医院ThomasJeffersonUniversityHosp止al的病理学副教授AgnieszkaK.Witkiewicz说Witkiewicz检查了97位三阴性乳腺癌患者,其中73人是白人,24人是非洲裔美国人用免疫组织化学技术评估了胰岛素样生长因子1受体IGB1R蛋白质表达,用显色原位杂交技术评估了IGF-1R基因拷贝的数量他们发觉在25%的病例中IGF-1R过度表达IGF-1R蛋白质过度表达与基因扩增有关联此外,这种受体的表达较低与更高的淋巴结转移风险有关,而较高的表达大致与更小的肿瘤尺寸有联系在55岁以下的患者中间,IGF-1R过度表达与更长的存活期有联系由于阻滞IGF-1R已经是一种治疗肉瘤的胜利疗法,W计kiewicz提出可能有潜力也在这种乳腺癌亚型中瞄准这种受体“眼下,我们知道它的存在而且我们知道这是一个更好的预后标记,Witkiewicz说“下一步将了解三阴性乳腺癌患者是否能从瞄准IGF-1R中受益”###在Twaer上关注AACR@AACR#AACR在Facebook上关注AACR美国癌症讨论学会AACR的使命是预防和治疗癌症美国癌症讨论学会AACR成立于1907年,它是世界上致力于促进癌症讨论的历史最悠久和最大的专业组织它的成员包括来自美国和其它90多个我国的
3.2万名基础、转化和临床讨论人员、卫生保健专业人士、癌症存活者和提倡者美国癌症讨论学会AACR引领来自癌症学界的各种专家技能从而通过高质量的科学和教育项目加速预防、诊断和治疗癌症的过程它为创新的优秀讨论供应资助,还供应讨论奖学金和癌症进展奖美国癌症讨论学会AACR年会吸引超过
1.8万名与会者共享该领域最新的发觉和进展一年中的特地会议上发表来自癌症讨论、治疗和患者护理的一大批专题的新数据美国癌症讨论学会AACR发表6种主要的同行评议杂志:《癌症讨论》CancerResearch、《临床癌症讨论》ClinicalCancerResearch、《分子癌症治疗学》MolecularCancerTherapeutics、《分子癌症讨论》MolecularCancerResearch、《癌症流行病学、生物标记与预防》CancerEpidemiologyBiomarkersPrevention以及《癌症预防讨论》CancerPreventionResearch美国癌症讨论学会AACR还出版《CR》杂志,这是一份面对癌症存活者及其家人、患者提倡者、医生和科学家的杂志《CR》为共享癌症讨论、生存和提倡的关键的基于证据的信息和观点供应了一个论坛Triple-negativebreastcancersmayhaveuniquetherapeutictargetDENVER—Patientswithtriple-negativebreastcanceroneofthehardestsubtypestotreatmayhaveauniquebiomarkerthatwouldenablethemtoreceivemoretargetedtherapyaccordingtodatapresentedattheFourthAACRInternationalConferenceonMolecularDiagnosticsinCancerTherapeuticDevelopment.Triple-negativebreastcancersarebreastcancersthathavetestednegativeforestrogenreceptorsprogesteronereceptorsandHER
2.Becauseofthisbiologythesecancersdonotrespondtoendocrinetherapiesortrastuzumab.Inothersubsetsofbreastcanceryoucanusethesedrugswithsomesuccess.Howevertriple-negativebreastcancerscurrentlylacktherapeutictargetsandaremanagedwithconventionalchemotherapysaidAgnieszkaK.WitkiewiczM.D.anassociateprofessorofpathologyatThomasJeffersonUniversityHospitalinPhiladelphia.Witkiewiczexamined97patientswithtriple-negativebreastcancerofwhom73werewhiteand24wereAfrican-American.Insulin-likegrowthfactor1receptorIGF-1RproteinexpressionwasevaluatedbyimmunohistochemistryandIGF-1Rgenecopynumberwasassessedbychromogenicinsituhybridization.TheyfoundthatIGF-1Rwasoverexpressedin25percentofthecases.TheIGF-1Rproteinoverexpressioncorrelatedwithgeneamplification.Moreoverlowexpressionofthereceptorwasassociatedwithgreaterriskoflymphnodemetastasisandhighexpressionshowedborderlineassociationwithlowertumorsize.Amongpatientsyoungerthan55yearsIGF-1Roverexpressionwasassociatedwithlongersurvival.SinceIGF-1RblockadehasbeenasuccessfultherapeuticapproachinsarcomasWitkiewiczsuggestedthattheremaybepotentialtotargetthisreceptorinthisbreastcancersubtypeaswell.FornowweknowthatitisthereandweknowitisamarkerofbetterprognosissaidWitkiewicz.Thenextstepistolearniftriple-negativebreastcancerpatientsbenefitfromtargetingIGF-1R.###FollowtheAACRonTwitter:@AACR#AACRFollowtheAACRonFacebook:htThemissionoftheAmericanAssociationforCancerResearchistopreventandcurecancer.Foundedin1907theAACRistheworldsoldestandlargestprofessionalorganizationdedicatedtoadvancingcancerresearch.Themembershipincludes32000basictranslationalandclinicalresearchers;healthcareprofessionals;andcancersurvivorsandadvocatesintheUnitedStatesandmorethan90othercountries.TheAACRmarshalsthefullspectrumofexpertisefromthecancercommunitytoaccelerateprogressinthepreventiondiagnosisandtreatmentofcancerthroughhigh-qualityscientificandeducationalprograms.Itfundsinnovativemeritoriousresearchgrantsresearchfellowshipsandcareerdevelopmentawards.TheAACRAnnualMeetingattractsmorethan18000participantswhosharethelatestdiscoveriesanddevelopmentsinthefield.SpecialConferencesthroughouttheyearpresentnoveldataacrossawidevarietyoftopicsincancerresearchtreatmentandpatientcare.TheAACRpublishessixmajorpeer-reviewedjournals:CancerResearchClinicalCancerResearch;MolecularCancerTherapeutics;MolecularCancerResearch;CancerEpidemiologyBiomarkersPrevention;andCancerPreventionResearch.TheAACRalsopublishesCRamagazineforcancersurvivorsandtheirfamiliespatientadvocatesphysiciansandscientistsprovidingaforumforsharingessentialevidence-basedinformationandperspectivesonprogressincancerresearchsurvivorshipandadvocacy.。